ASA404 lung ca trial expanded

December 1, 2007
Oncology NEWS International, Oncology NEWS International Vol 16 No 12, Volume 16, Issue 12

ASA404 lung cancer trial expanded

LONDON—Antisoma plc announced that its licensing partner Novartis plans to start a pivotal phase III trial of ASA404 in non-small-cell lung cancer in early 2008. This trial has been expanded to include patients with nonsquamous as well as squamous disease, a change that more than doubles the population of NSCLC patients addressed by the trial.